| Sonstiges: |
- Nachgewiesen in: USPTO Patent Applications
- Sprachen: English
- Document Number: 20230183375
- Publication Date: June 15, 2023
- Appl. No: 17/925061
- Application Filed: May 14, 2021
- Assignees: Fundação Universidade Federal do ABC - UFABC (Santo André, BR), Technische Universität Braunschweig (Braunschweig, DE)
- Claim: 1. An antibody, or a fragment thereof, comprising an amino acids sequence with at least 95% similarity to any of the SEQ ID #2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26.
- Claim: 2. The antibody, or a fragment thereof, according to claim 1, wherein the antibody comprises the amino acids sequence as described in any of SEQ ID #2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26.
- Claim: 3. The antibody, or a fragment thereof, according to claim 1, wherein the antibody consists of the amino acids sequence as described in any of SEQ ID #2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26.
- Claim: 4. The antibody, or a fragment thereof, according to claim 1, wherein the antibody is an scFv, scFv-Fc or IgG antibody, preferably an scFv antibody.
- Claim: 5. (canceled)
- Claim: 6. A nucleotide sequence encoding an antibody, or a fragment thereof, as described in claim 1.
- Claim: 7. The nucleotide sequence, according to claim 6, characterized by, wherein the nucleotide sequence comprises a nucleic acid sequence with at least 95% similarity to any one of SEQ ID #1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25.
- Claim: 8. The nucleotide sequence, according to claim 6, wherein the nucleotide sequence comprises a nucleic acid sequence as described in any one of SEQ ID #1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25.
- Claim: 9. The nucleotide sequence, according to claim 6, wherein the nucleotide sequence consists of the nucleic acid sequence as described in any one of SEQ ID #1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25.
- Claim: 10. A composition comprising an antibody, or a fragment thereof, as defined in claim 1.
- Claim: 11. The composition, according to claim 10, formulated for topical use.
- Claim: 12. The composition, according to claim 10, in the form of a suspension, emulsion, spray lotion, unguent, cream, gel, plaster, film, ointment or incorporated into patches.
- Claim: 13. The composition, according to claim 10, in the form of a gel, lotion, cream or ointment.
- Claim: 14. The composition, according to claim 13, in the form of a hydrogel.
- Claim: 15. The composition, according to claim 12, wherein the gel is a poloxamer-based hydrogel.
- Claim: 16. The composition, according to claim 15, wherein the poloxamer is poloxamer 407 and/or poloxamer 403.
- Claim: 17. The composition, according to claim 10, for use as a medication.
- Claim: 18. (canceled)
- Claim: 19. (canceled)
- Claim: 20. (canceled)
- Claim: 21. (canceled)
- Claim: 22. A method for treating or preventing KLK7-related diseases or disorders, comprising administering an antibody, or fragment thereof, as defined in claim 1, or a composition comprising an antibody, to an subject in need thereof.
- Claim: 23. A method according to claim 22, characterized by the fact that the KLK7-related diseases or disorders are due to an increased activity of KLK7.
- Claim: 24. A method according to claim 22, characterized by the fact that the disease or disorder is a dermatological pathology.
- Claim: 25. A method according to claim 22, characterized by the fact that the dermatological pathology is selected from atopic dermatitis, psoriasis and Netherton syndrome.
- Current International Class: 07; 61; 61; 61
|
